- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07854730
Effect of Ventilator Hyperinflation Combined With Body Positioning on ABG in VAP
Effect of Ventilator Hyperinflation Combined With Body Positioning on Arterial Blood Gases In Patients With Ventilator-Associated Pneumonia : A Randomized Controlled Trial
This study aims to evaluate the effect of ventilator hyperinflation combined with body positioning on arterial blood gases in patients with ventilator-associated pneumonia. Forty-two mechanically ventilated patients will be randomly assigned into two groups receiving the intervention in either supine or lateral decubitus positions. Arterial blood gases will be assessed over a 6-day intervention period. The findings are expected to provide evidence regarding the optimal positioning strategy to enhance the effectiveness of ventilator hyperinflation in improving gas exchange in critically ill patients.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Cairo, Egipto, 11571
- Reclutamiento
- Mohamed Saied Zidan
-
Contacto:
- Mohamed S Zidan, phd
- Número de teléfono: 01016469801
- Correo electrónico: drmohzidan2015@gmail.com
-
Contacto:
- Mohamed S Zidan
- Número de teléfono: 01016469801
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Mechanically ventilated patients ≥ 48 hours
- Diagnosed with VAP (clinical + chest X-ray)
- Age: 40-60 years
- Hemodynamically stable
- Unilateral lung involvement
Exclusion Criteria:
- Bilateral lung disease
- Unstable cardiovascular conditions
- Contraindications to positioning
- Re-intubation cases
- Presence of pneumothorax or air leak
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: ventilator hyperinflation from lateral decubitus position
This group will receive Ventilator hyperinflation in lateral decubitus position (affected lung uppermost) and Conventional respiratory physiotherapy |
a therapeutic technique used by clinicians (Manual or Ventilator Hyperinflation) to clear secretions and recruit collapsed lung tissue, or an inadvertent complic |
|
Experimental: Manual hyperinflation for Lateral decubitus position
This group will receive manual hyperinflation in Lateral decubitus position and Conventional respiratory physiotherapy |
a respiratory therapy technique that uses a manual resuscitation bag to deliver larger-than-normal, controlled breaths to clear airway secretions and reopen collapsed lung areas |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
PaCO2
Periodo de tiempo: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
partial pressure of carbon dioxide in arterial blood, measuring how effectively the lungs eliminate carbon dioxide |
Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
|
PaO2
Periodo de tiempo: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
partial pressure of oxygen dissolved in arterial blood plasma, measured through an Arterial Blood Gas (ABG) test. |
Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
|
SaO2
Periodo de tiempo: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
the percentage of oxygen-saturated hemoglobin relative to total hemoglobin in arterial blood, typically measured via an invasive arterial blood gas (ABG) analysis with normal values ranging from 95% to 99% |
Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
|
PaO2/FiO2 (P/F)
Periodo de tiempo: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
a clinical metric used to evaluate oxygenation efficiency and diagnose the severity of acute hypoxemic respiratory failure or Acute Respiratory Distress Syndrome (ARDS). |
Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Pulmonary compliance
Periodo de tiempo: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
the change in lung volume divided by the change in pressure (Δ V / Δ P). Higher compliance means the lungs stretch easily; lower compliance means they are stiff and harder to inflate |
Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IRB # 14/5/2025-2026
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .